An X-ray study of CIV-selected AGN in the COSMOS field

Negli ultimi vent’anni innumerevoli sforzi sono stati compiuti a livello internazionale per ottenere un censimento completo degli “Active Galactic Nuclei” (AGN), ovvero di nuclei galattici attivi, oscurati in banda X. Tale censimento potrebbe rappresentare infatti la soluzione alla problematica del cosiddetto fondo cosmico non risolto in banda X. Gli studi finora condotti sfruttano la forte correlazione fra l'attività del SMBH e l'evoluzione della galassia ospite attraverso osservazioni in banda X hard, nel vicino-medio infrarosso e nell'ottico. Questa tesi si colloca in questo scenario con lo scopo di verificare e confermare l'affidabilità della selezione tramite la riga di emissione del CIV a 1549 Å di AGN oscurati fino a z≈3. Per raggiungere tale obiettivo è stato assunto che il CIV rappresenti un indicatore affidabile della luminosità intrinseca degli AGN e del loro alto potenziale di ionizzazione. Inoltre, allo studio in banda ottica delle sorgenti sono stati associati i dati profondi in banda X per analizzarne le proprietà X e caratterizzarne l’ammontare dell’oscuramento in tale banda in termini di densità di colonna di idrogeno. In particolare, in questo lavoro vengono presentati i risultati dell’analisi in banda X del campione di 192 AGN selezionati nella survey ottica zCOSMOS-Deep, attraverso la riga di emissione del CIV a 1549 Å. Queste 192 sorgenti hanno un redshift medio di 2.2 e una magnitudine media AB in banda B di 23.7. La copertura in banda X del campo selezionato è data dalla survey Chandra COSMOS-Legacy comprendente 4.6 Ms di osservazioni in un’area di 2.2 deg2. I risultati ottenuti in questo progetto di tesi tramite la selezione possono ritenersi soddisfacenti: metà delle AGN di Tipo 2 selezionate con il CIV e rilevate in banda X risultano fortemente oscurate (NH>10^23 cm^(-2) ). Inoltre, le AGN di Tipo 2 non rilevate in banda X risultano consistenti con uno scenario di oggetti oscurati.

Macrophages and dendritic cells express tight junction proteins and exchange particles in an in vitro model of the human airway wall

The human airway epithelium serves as structural and functional barrier against inhaled particulate antigen. Previously, we demonstrated in an in vitro epithelial barrier model that monocyte derived dendritic cells (MDDC) and monocyte derived macrophages (MDM) take up particulate antigen by building a trans-epithelial interacting network. Although the epithelial tight junction (TJ) belt was penetrated by processes of MDDC and MDM, the integrity of the epithelium was not affected. These results brought up two main questions: (1) Do MDM and MDDC exchange particles? (2) Are those cells expressing TJ proteins, which are believed to interact with the TJ belt of the epithelium to preserve the epithelial integrity? The expression of TJ and adherens junction (AJ) mRNA and proteins in MDM and MDDC monocultures was determined by RT-PCR, and immunofluorescence, respectively. Particle uptake and exchange was quantified by flow cytometry and laser scanning microscopy in co-cultures of MDM and MDDC exposed to polystyrene particles (1 μm in diameter). MDM and MDDC constantly expressed TJ and AJ mRNA and proteins. Flow cytometry analysis of MDM and MDDC co-cultures showed increased particle uptake in MDDC while MDM lost particles over time. Quantitative analysis revealed significantly higher particle uptake by MDDC in co-cultures of epithelial cells with MDM and MDDC present, compared to co-cultures containing only epithelial cells and MDDC. We conclude from these findings that MDM and MDDC express TJ and AJ proteins which could help to preserve the epithelial integrity during particle uptake and exchange across the lung epithelium.

A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study

Intravenous immunoglobulin (IVIG) is the first-line therapy for multifocal motor neuropathy (MMN). This open-label multi-centre study (NCT00701662) assessed the efficacy, safety, and convenience of subcutaneous immunoglobulin (SCIG) in patients with MMN over 6 months, as an alternative to IVIG. Eight MMN patients (42-66 years), on stable IVIG dosing, received weekly SCIG at doses equivalent to previous IVIG using a "smooth transition protocol". Primary efficacy endpoint was the change from baseline to week 24 in muscle strength. Disability, motor function, and health-related quality of life (HRQL) endpoints were also assessed. One patient deteriorated despite dose increase and was withdrawn. Muscle strength, disability, motor function, and health status were unchanged in all seven study completers who rated home treatment as extremely good. Four experienced 18 adverse events, of which only two were moderate. This study suggests that MMN patients with stable clinical course on regular IVIG can be switched to SCIG at the same monthly dose without deterioration and with a sustained overall improvement in HRQL.